Survodutide
An investigational dual GCGR/GLP-1R agonist studied in obesity and metabolic liver-disease clinical research programs.
What Survodutide is
Survodutide (BI 456906) is an investigational peptide agonist designed to activate both the glucagon receptor and the GLP-1 receptor. The dual-agonist rationale combines GLP-1-linked appetite and glycemic effects with glucagon-linked energy-expenditure and hepatic-metabolism effects. Peer-reviewed Phase 2 work in adults with obesity reported dose-dependent body-weight reductions over multi-month once-weekly subcutaneous regimens, and additional studies have examined cirrhosis pharmacokinetics and broader cardiometabolic markers.
This compound is advancing through sponsored clinical development programs (including SYNCHRONIZE trial designs). That clinical-development context is not the same thing as research-grade bulk peptide sold for laboratory use.
Critical compliance note: research-grade survodutide is Research Use Only. It is not an FDA-approved drug product, not a finished clinical-trial medication kit for consumer use, and not for human consumption. Any mg-range figures below summarize published trial literature for education only.
Survodutide has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
Survodutide co-activates the glucagon receptor (GCGR) and GLP-1 receptor. GLP-1 receptor engagement supports satiety signaling, delayed gastric emptying, and glucose-dependent insulinotropic effects. Glucagon receptor engagement is studied for increases in energy expenditure, fat oxidation, and hepatic lipid handling. The dual profile is intended to differentiate from GLP-1 monoagonists in weight-loss magnitude and liver-fat biology, which is why MASLD/MASH endpoints appear in the development program.
The research context
Obesity-medicine researchers, hepatology groups focused on metabolic liver disease, and incretin-pharmacology labs are the primary audience. Comparative work against GLP-1 monoagonists and other dual/triple agonists is a major theme.
What the research examines
These describe where the compound shows up in published work. None of them should be read as an established outcome.
How it appears in the literature
What the published work actually used. Reference only, not instructions.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Phase 2 obesity dose-finding trial (once-weekly subcutaneous survodutide) | 600 mcg – 4.8 mg | once weekly | subcutaneous |
| Lower titration band within the same development literature | 600 mcg – 2.4 mg | once weekly after escalation | subcutaneous |
Handling & storage
Lyophilized research material should be kept cold, dry, and dark. Reconstituted solutions belong in refrigerated storage with aliquotting to limit freeze-thaw, following the laboratory SOP.
Notes on combined research
In research practice, survodutide is usually compared with semaglutide, tirzepatide, or other next-generation agonists rather than stacked with them. Combination experimental arms, when used, are designed to dissect receptor contributions, not to create consumer stacks.
Survodutide questions
Published Phase 2 obesity research evaluated roughly 0.6 mg to 4.8 mg once weekly subcutaneously. That describes investigational clinical-trial product exposures, not research-grade RUO instructions.
As an investigational dual agonist it has been studied in clinical trials, but research-grade material is RUO and not an approved finished drug product for consumer or clinical substitution use.
Semaglutide is a GLP-1 receptor monoagonist. Survodutide is designed to activate both glucagon and GLP-1 receptors, adding glucagon-pathway metabolic effects to incretin biology.
Dual GCGR/GLP-1R pharmacology is being studied for effects on liver fat and related metabolic-liver endpoints in addition to body weight.
No. Sponsored clinical-trial drug product and bulk laboratory RUO peptide are different supply and regulatory categories. RUO material is not for human consumption.
As with other incretin-based agonists, gastrointestinal adverse events are a prominent class-level theme and influence dose-escalation design.
Long-acting designs usually involve careful concentration verification, stable reconstitution practices, and PK sampling schedules matched to multi-day exposure.
Read the research yourself
Verified against PubMed, one by one. A reference you cannot open is not evidence.
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.PubMed
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.PubMed
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).PubMed
- Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.PubMed